心脏衰竭中的心房结节功能障碍:从病理生理学到治疗视角的新视野
Isabella Fumarulo1,2, Elia Nunzio Maria Salerno1,2, Andrea De Prisco1,2
1Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Journal of cardiovascular development and disease
|August 27, 2025
概括
心力衰竭 (HF) 涉及心肌和导电组织的不良重塑. 本综述探讨了心房结节功能障碍,其临床影响以及当前/未来的治疗方法.
科学领域:
- 心脏病学
- 电生理学
- 心脏衰竭的研究
背景情况:
- 心脏衰竭 (HF) 涉及到心肌细胞和心脏导电系统的不良重塑.
- 心房节 (AV) 功能障碍是HF的常见并发症,导致导电延迟和异步.
- HF患者的临床结果通常与AV节点功能障碍有关,但其病理学尚未得到充分研究.
研究的目的:
- 在HF的背景下调查AV节点功能障碍的病理生理学.
- 阐明AV结节功能障碍对HF患者的临床影响.
- 审查目前的治疗策略,并探索潜在的未来治疗AV节点功能障碍.
主要方法:
- 现有关于HF和AV节点病理学的文献综述.
- 分析连接HF和AV节点功能障碍的病理生理机制.
- 关于心血管结节功能障碍结果的临床数据综合.
主要成果:
- 由HF引起的重塑会对心血管节点的结构和功能产生重大影响.
- 动脉节功能障碍导致心律失常和HF的预后不佳.
- 目前的治疗方法对HF中AV节点特异性病理的疗效有限.
结论:
- 了解心血管结节病理学对于改善患者的治疗结果至关重要.
- 针对静脉动脉节功能障碍提供了潜在的治疗途径.
- 需要进一步的研究来开发有效的治疗方法.
相关概念视频
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Pathophysiology of Cardiac Performance
799
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
799


